IL107398A - Promote drugs, their preparation and use as drugs - Google Patents

Promote drugs, their preparation and use as drugs

Info

Publication number
IL107398A
IL107398A IL10739893A IL10739893A IL107398A IL 107398 A IL107398 A IL 107398A IL 10739893 A IL10739893 A IL 10739893A IL 10739893 A IL10739893 A IL 10739893A IL 107398 A IL107398 A IL 107398A
Authority
IL
Israel
Prior art keywords
beta
glucuronyloxy
compound
drug
acid
Prior art date
Application number
IL10739893A
Other languages
English (en)
Hebrew (he)
Other versions
IL107398A0 (en
Original Assignee
Behringwerke Ag
Hoechst Sa Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag, Hoechst Sa Lab filed Critical Behringwerke Ag
Publication of IL107398A0 publication Critical patent/IL107398A0/xx
Publication of IL107398A publication Critical patent/IL107398A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL10739893A 1992-10-27 1993-10-25 Promote drugs, their preparation and use as drugs IL107398A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4236237A DE4236237A1 (de) 1992-10-27 1992-10-27 Prodrugs, ihre Herstellung und Verwendung als Arzneimittel

Publications (2)

Publication Number Publication Date
IL107398A0 IL107398A0 (en) 1994-01-25
IL107398A true IL107398A (en) 2001-01-28

Family

ID=6471460

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10739893A IL107398A (en) 1992-10-27 1993-10-25 Promote drugs, their preparation and use as drugs

Country Status (12)

Country Link
US (2) US5955100A (ko)
EP (1) EP0595133B1 (ko)
JP (1) JP3841311B2 (ko)
KR (1) KR100297862B1 (ko)
AT (1) ATE494009T1 (ko)
AU (1) AU669218B2 (ko)
CA (1) CA2109259C (ko)
DE (2) DE4236237A1 (ko)
IL (1) IL107398A (ko)
NO (1) NO311830B1 (ko)
NZ (1) NZ250030A (ko)
ZA (1) ZA937951B (ko)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19512484A1 (de) * 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
DK0751144T3 (da) 1995-06-27 2004-12-27 Pharmachemie Bv Nye antracyclin-pro-drugs, fremgangsmåde til fremstilling deraf samt antitumorsammensætninger og et komponentkit indeholdende disse pro-drugs
DE19524515A1 (de) * 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharid-Konjugate
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
GB9600471D0 (en) * 1996-01-10 1996-03-13 Univ London Pharmacy Drug delivery system
ATE316799T1 (de) * 1996-03-12 2006-02-15 Sanofi Aventis Deutschland Neuartige prodrugs für die therapie von tumoren und entzündlichen erkrankungen
ATE310538T1 (de) 1996-04-15 2005-12-15 Asahi Chemical Ind Arzneimittelkomplexe enthaltend taxan- verbindungen oder steroiden
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
ATE210673T1 (de) * 1996-09-30 2001-12-15 Bayer Ag Glycokonjugate von modifizierten camptothecin- derivaten (20-o-verknüpfung)
DE19640207A1 (de) * 1996-09-30 1998-04-02 Bayer Ag Glycokonjugate von modifizierten Camptothecin-Derivaten (A- oder B-Ring-Verknüpfung)
AU7201998A (en) * 1997-05-06 1998-11-27 Zhi Liu Drug delivery system
ID23424A (id) * 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE69918950T2 (de) 1998-02-06 2005-07-28 De Montfort University Durch hydroxylierung aktivierte medikamentvorstufen
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
DE69909073T2 (de) * 1998-02-12 2004-05-19 De Montfort University Durch hydroxylierung aktivierte wirkstofffreigabe
US6287602B1 (en) * 1998-09-16 2001-09-11 Oncopharmaceutical, Inc. Treatment of oncologic tumors with an injectable formulation of a Golgi apparatus disturbing agent
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
FR2791679B1 (fr) * 1999-03-31 2003-04-11 Fabre Pierre Dermo Cosmetique Bioprecurseurs aptes a liberer un derive retinoique par mise a profit de l'activite enzymatique de la surface cutanee et compositions pharmaceutiques et/ou cosmetiques
ATE301129T1 (de) 1999-05-04 2005-08-15 Strakan Int Ltd Androgen glykoside und die androgenische aktivität davon
DE19925810A1 (de) * 1999-06-07 2000-12-14 Paz Arzneimittelentwicklung Anwendung von Verapamil und Verapamilderivaten zur Herstellung von Arzneimitteln mit Glucuronidase hemmender Wirkung
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6638312B2 (en) 2000-08-04 2003-10-28 Depuy Orthopaedics, Inc. Reinforced small intestinal submucosa (SIS)
US7220824B1 (en) 2000-08-28 2007-05-22 Bayer Aktiengesellschaft Integrin-mediated drug targeting
US6642205B2 (en) * 2000-09-25 2003-11-04 Pro-Pharmaceuticals, Inc. Methods and compositions for reducing side effects in chemotherapeutic treatments
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
EP1238678A1 (en) 2001-03-08 2002-09-11 Bayer Aktiengesellschaft Enzyme-activated cytostatic conjugates with integrin ligands
EP1416888A4 (en) 2001-07-16 2007-04-25 Depuy Products Inc DEVICE AND METHOD FOR REGENERATING THE MENISCUS
US7819918B2 (en) 2001-07-16 2010-10-26 Depuy Products, Inc. Implantable tissue repair device
US8025896B2 (en) 2001-07-16 2011-09-27 Depuy Products, Inc. Porous extracellular matrix scaffold and method
US7201917B2 (en) 2001-07-16 2007-04-10 Depuy Products, Inc. Porous delivery scaffold and method
US8012205B2 (en) 2001-07-16 2011-09-06 Depuy Products, Inc. Cartilage repair and regeneration device
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
CA2468479C (en) * 2001-12-03 2010-04-27 Universitaetsklinikum Charite Der Humboldt-Universitaet Zu Berlin Technologietransferstelle Podophyllotoxins as antiproliferative agents
JP4342314B2 (ja) * 2001-12-17 2009-10-14 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド 病変部位への特異的送達のための開裂薬剤
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
NZ537686A (en) * 2002-06-20 2007-01-26 Nippon Suisan Kaisha Ltd A beta2 agonist prodrug having reduced side effects
US20040152769A1 (en) * 2002-11-09 2004-08-05 Ekwuribe Nnochiri Nkem Modified carbamate-containing prodrugs and methods of synthesizing same
AU2003294796A1 (en) * 2002-12-05 2004-06-23 Schering Ag Epothilone analogs for site specific delivery in the treatment of proliferative diseases
DE10256982A1 (de) 2002-12-05 2004-06-24 Schering Ag Neue Effektor-Konjugate, Verfahren zu Ihrer Herstellung und Ihre Pharmazeutische Verwendung
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
EP1599196A4 (en) * 2003-01-17 2006-05-31 Threshold Pharmaceuticals Inc ANTICANCER THERAPY
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
WO2005034856A2 (en) * 2003-09-05 2005-04-21 The Regents Of The University Of Colorado Targeted drug-formaldehyde conjugates and methods of making and using the same
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
US7825096B2 (en) * 2004-09-08 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
EP1809656A4 (en) 2004-09-29 2009-03-25 Amr Technology Inc CYCLOSPORINAL KINANALOGA AND ITS PHARMACEUTICAL APPLICATIONS
WO2006041631A2 (en) 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
TW200631586A (en) * 2005-03-08 2006-09-16 Phytohealth Corp A method for preparing a pharmaceutical compound by way of magnetic carbon nanocapsules
CA2602849C (en) 2005-03-30 2013-06-04 Saladax Biomedical Inc. Doxorubicin immunoassay
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
EP2037954A4 (en) * 2006-06-20 2011-09-14 Janssen Pharmaceutica Nv METHOD FOR MODULATING PHARMACOKINETICS AND METABOLISM OF THERAPEUTIC USE
US20080031866A1 (en) * 2006-06-20 2008-02-07 Eichenbaum Gary M Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
US7871440B2 (en) 2006-12-11 2011-01-18 Depuy Products, Inc. Unitary surgical device and method
US7792651B2 (en) * 2007-04-26 2010-09-07 General Electric Company Methods and systems for computing gear modifications
WO2008153394A2 (en) * 2007-06-14 2008-12-18 Academisch Medisch Centrum Novel anti-inflammatory pro-drugs
MX2010004400A (es) 2007-10-23 2010-05-20 Nektar Therapeutics Polimeros de multiples brazos dirigidos a la hidroxiapatita y conjugados de estos.
EP2249921B1 (en) 2008-02-25 2020-06-17 Eyegate Pharmaceuticals, Inc. Enhanced delivery of dexamethasone phosphate to ocular tissues through iontophoresis
CN102159247A (zh) * 2008-07-30 2011-08-17 日东电工株式会社 药物载体
JP2013510163A (ja) * 2009-11-06 2013-03-21 チェルシー・セラピューティクス，インコーポレイテッド 酵素阻害化合物
KR101253399B1 (ko) 2010-10-26 2013-04-11 영남대학교 산학협력단 아포지단백질 ａ－ｉ 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
EP2468741A1 (en) 2010-12-16 2012-06-27 Bel/Novamann International s.r.o. Novel quercetin derivatives, their preparation, pharmaceutical compositions containing them and their use
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2014080251A1 (en) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
KR20150095870A (ko) 2012-12-17 2015-08-21 패리온 사이언스 인코퍼레이티드 3,5-디아미노-6-클로로-n-(n-(4-페닐부틸)카르밤이미도일)피라진-2-카르복스아미드 화합물
AU2013363218B2 (en) 2012-12-17 2018-03-15 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
DK3122757T3 (da) 2014-02-28 2023-10-09 Hangzhou Dac Biotech Co Ltd Ladede linkere og anvendelse deraf til konjugering
JP6759326B2 (ja) 2015-07-12 2020-09-23 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 細胞結合分子の共役のための架橋連結体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
AU2016429272A1 (en) 2016-11-14 2019-05-02 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
WO2019121734A1 (en) 2017-12-21 2019-06-27 Pharmacytics B.V. Method for improving the oral bioavailability of a drug
BR112021008232A2 (pt) 2018-11-05 2021-08-03 Bayer Pharma Aktiengesellschaft conjugados citostáticos inovadores com ligantes de integrina
KR20240105377A (ko) 2021-10-04 2024-07-05 빈서스 파마 게엠베하 과증식성 질환의 치료, 예방 또는 관리를 위한 화합물, 약학 조성물 및 방법
WO2023057812A1 (en) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorder
EP4412656A1 (en) 2021-10-04 2024-08-14 Vincerx Pharma GmbH Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
US4279992A (en) * 1978-03-13 1981-07-21 Miles Laboratories, Inc. Specific binding assay employing an enzyme-cleavable substrate as label
US4481195A (en) * 1978-10-13 1984-11-06 Adolf Schwimmer Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals
US4265885A (en) * 1978-10-25 1981-05-05 Farmitalia Carlo Erba S.P.A. Anthracyclines containing branched-chain amino-deoxy sugars
WO1981001145A1 (en) * 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
DK406686D0 (da) * 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US5434247A (en) * 1986-10-10 1995-07-18 Board Of Regents, The University Of Texas System Peptides for inducing monocyte cytotoxicity in diagnostics
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
IL106992A (en) * 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
DE3842836A1 (de) * 1988-12-20 1990-06-21 Behringwerke Ag Rhodomycine mit einer modifizierten kohlenhydrat-einheit
DK24089D0 (da) * 1989-01-20 1989-01-20 Hans Bundgaard Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups
US5433955A (en) * 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
DE3924655A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Anthracyclin-derivate
DE3928659A1 (de) * 1989-08-30 1991-03-07 Bayer Ag Ketophosphamidglycoside, verfahren zu ihrer herstellung sowie ihre verwendung als pharmazeutische wirkstoffe
DE3935016A1 (de) * 1989-10-20 1991-04-25 Behringwerke Ag Glycosyl-etoposid-prodrugs, verfahren zu ihrer herstellung und ihre anwendung in kombination mit funktionalisiertem tumorspezifischen enzym-konjugaten
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991009831A1 (en) * 1989-12-26 1991-07-11 Nova Pharmaceutical Corporation Prodrug anhydrides of asprin, indomethacin and ibuprofen, their preparation, compositions, and anti-inflammatory method of use
DE4002888A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Anthracyclin-glycosyl-prodrugs, verfahren zu ihrer herstellung und ihre verwendung in kombination mit funktionalisierten tumorspezifischen enzymkonjugaten
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
GB9017024D0 (en) * 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
WO1992004048A2 (en) * 1990-08-30 1992-03-19 The Biomembrane Institute Inhibition of metastasis potential and invasiveness by oligosaccharides or oligosaccharide antigens or antibodies
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.

Also Published As

Publication number Publication date
JP3841311B2 (ja) 2006-11-01
US6146658A (en) 2000-11-14
ZA937951B (en) 1995-07-05
KR940008685A (ko) 1994-05-16
KR100297862B1 (ko) 2001-10-24
ATE494009T1 (de) 2011-01-15
NO311830B1 (no) 2002-02-04
NO933854D0 (no) 1993-10-26
AU669218B2 (en) 1996-05-30
NZ250030A (en) 1994-12-22
IL107398A0 (en) 1994-01-25
JPH06293665A (ja) 1994-10-21
CA2109259A1 (en) 1994-04-28
CA2109259C (en) 2005-05-24
EP0595133A3 (de) 1998-11-04
NO933854L (no) 1994-04-28
US5955100A (en) 1999-09-21
AU5022593A (en) 1994-05-12
EP0595133B1 (de) 2011-01-05
DE4236237A1 (de) 1994-04-28
DE59310399D1 (de) 2011-02-17
EP0595133A2 (de) 1994-05-04

Similar Documents

Publication Publication Date Title
US6146658A (en) Prodrugs, their preparation and use as pharmaceuticals
JP4392065B2 (ja) 腫瘍および炎症性疾患治療用の新規プロドラッグ
CA2429781C (en) Linkable sialyl lewis x analogs
KR100385830B1 (ko) 효소에의해활성화되는프로드럭
JPH1129497A (ja) インビボ許容性の向上した製剤
US5466681A (en) Receptor conjugates for targeting penicillin antibiotics to bacteria
CA2546784A1 (en) Glycomimetic antagonists for both e- and p-selectins
JP3004297B2 (ja) リゾスフィンゴ脂質誘導体
KR19980703591A (ko) 당 개질된 세포 증식 억제제
HU210147B (en) Process for producing antibody-drug conjugates and pharmaceutical compositions containing them
US20160038615A1 (en) Saccharide conjugates
WO2003086475A1 (en) Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
EP0953357A1 (en) Nephrotropic drugs
US20080312162A1 (en) Methods and Compositions for Enzyme-Specific Activation of Carbohydrate-Conjugated Prodrugs
EP0598719B1 (en) Receptor conjugates for targeting drugs and other agents
MXPA97001832A (en) New profarmacos for inflamator tumors and disease therapy

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired